검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 2개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Polatuzumab Vedotin | Pegfilgrastim |
Overview Company | Roche / Genentech | Amgen |
Overview Modality | ADC | ADC |
Overview Target | FRα | Ovarian Cancer |
Overview Indication | Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Cancer; Colon Cancer |
Overview Phase | PHASE_3 | PHASE_3 |
Overview Status | RECRUITING | RECRUITING |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | Pegfilgrastim products are colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functiona |
MoA Biomarker | CD20 expression | PD-L1-high |
PK/PD Half-life | 12.2 h | 80 days |
PK/PD Species | Rat | Cynomolgus monkey, NHP |
PK/PD Animal (cat.) | Rat, In vitro | Human, NHP |
PK/PD Experiment | pharmacokinetic | Pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | Cynomolgus monkey, NHP, Rat |
Toxicology Animal (cat.) | Mouse, Rat, NHP | Rat |
Toxicology Major finding | Hepatotoxicity: Monitor liver enzymes and bilirubin | Thrombocytopenia: Monitor platelet count ( 5 |
Clinical Primary efficacy | ORR 100% | ORR 56.7% |
Clinical ORR | 100.0% | 56.7% |
Clinical PFS | — | 10.1 |
Clinical OS | — | 24.6 |
Clinical Result source | ClinicalTrials.gov NCT02611323 | ClinicalTrials.gov NCT00911170 |
Clinical Data Tier / Score | S · 92 | C · 70 |
Clinical Program phase | PHASE_3 | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) | 2026년 7월 6일 (21일 전 · 갱신 권장) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 2개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Polatuzumab Vedotin | Pegfilgrastim |
Overview Company | Roche / Genentech | Amgen |
Overview Modality | ADC | ADC |
Overview Target | FRα | Ovarian Cancer |
Overview Indication | Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Cancer; Colon Cancer |
Overview Phase | PHASE_3 | PHASE_3 |
Overview Status | RECRUITING | RECRUITING |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | Pegfilgrastim products are colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functiona |
MoA Biomarker | CD20 expression | PD-L1-high |
PK/PD Half-life | 12.2 h | 80 days |
PK/PD Species | Rat | Cynomolgus monkey, NHP |
PK/PD Animal (cat.) | Rat, In vitro | Human, NHP |
PK/PD Experiment | pharmacokinetic | Pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | Cynomolgus monkey, NHP, Rat |
Toxicology Animal (cat.) | Mouse, Rat, NHP | Rat |
Toxicology Major finding | Hepatotoxicity: Monitor liver enzymes and bilirubin | Thrombocytopenia: Monitor platelet count ( 5 |
Clinical Primary efficacy | ORR 100% | ORR 56.7% |
Clinical ORR | 100.0% | 56.7% |
Clinical PFS | — | 10.1 |
Clinical OS | — | 24.6 |
Clinical Result source | ClinicalTrials.gov NCT02611323 | ClinicalTrials.gov NCT00911170 |
Clinical Data Tier / Score | S · 92 | C · 70 |
Clinical Program phase | PHASE_3 | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) | 2026년 7월 6일 (21일 전 · 갱신 권장) |
추천 비교
추천 비교